June 23, 2014
Pres. Hasegawa, Other Execs Bow Deeply at Tokyo Press Conference Takeda Pharmaceutical had an improper systematic involvement in an investigator-initiated clinical trial comparing its angiotensin receptor blocker Blopress (candesartan) and the calcium channel blocker amlodipine, a third-party investigation has found...read more